Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 01 Feb 2023
Mark Cuban Cost Plus Drug Company and OncoPower team up to bring medication adherence and cost savings to cancer patients
30 January 2023 - Collaboration focuses on pricing transparency, affordable access, and engaging patients at home to ensure treatment adherence. ...
Posted by Michael Wonder on 01 Feb 2023
Simcere’s COVID-19 pill goes on sale in China at less than half the price of Pfizer’s Paxlovid
31 January 2023 - The retail price of Simcere Pharmaceutical’s orally taken COVID-19 treatment, which was only approved to go ...
Posted by Michael Wonder on 01 Feb 2023
Nintedanib esylate for the treatment of adults with idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
1 February 2023 - Nintedanib esylate is recommended as an option for the treatment of adults with idiopathic pulmonary fibrosis ...
Posted by Michael Wonder on 01 Feb 2023
ABPI response to new MHRA fees announced for 1 April 2023
1 February 2023 - These fee increases are an important step to ensuring the MHRA has the resources it needs ...
Posted by Michael Wonder on 01 Feb 2023
Somatrogon for treating growth disturbance in people 3 years and over
1 February 2023 - Somatrogon is recommended as an option for the treatment of children 3 years of age and over ...
Posted by Michael Wonder on 01 Feb 2023
Mesoblast resubmits biologic license application to FDA for remestemcel-L in children with steroid-refractory acute graft versus host disease
31 January 2023 - New 4 year data from the Phase 3 trial shows durable long term survival outcomes. ...
Posted by Michael Wonder on 01 Feb 2023
Trastuzumab deruxtecan for treating HER2 positive unresectable or metastatic breast cancer after one or more anti-HER2 treatments
1 February 2023 - Trastuzumab deruxtecan is recommended with managed access as an option for the treatment of adults with HER2 ...
Posted by Michael Wonder on 01 Feb 2023
Artiva Biotherapeutics receives FDA fast track designation for AB-101
31 January 2023 - Granted fast track designation by US FDA for the treatment of relapsed/refractory non-Hodgkin lymphoma of B cell ...
Posted by Michael Wonder on 01 Feb 2023
Upadacitinib monohydrate for the treatment of patients with active non-radiographic axial spondyloarthritis
1 February 2023 - Upadacitinib monohydrate is recommended as an option for the treatment of adults with active non-radiographic axial ...
Posted by Michael Wonder on 01 Feb 2023
Changes applying to evaluation of new substances for listed medicines
1 February 2023 - The TGA has introduced Mandatory requirements for applications to vary the Permissible Ingredients Determination under section 26BD ...
Posted by Michael Wonder on 01 Feb 2023
New Parkinson's disease treatment added to PBS
1 February 2023 - From 1 February, Australians with Parkinson’s disease will have access to a new medicine on the PBS. ...
Posted by Michael Wonder on 01 Feb 2023
Use of Clinical Trials Information System becomes mandatory for new clinical trial applications in the EU
31 January 2023 - From 31 January 2023, all initial clinical trial applications in the European Union must be submitted via ...
Posted by Michael Wonder on 31 Jan 2023
US health care from a global perspective, 2022: accelerating spending, worsening outcomes
31 January 2023 - In the previous edition of US Health Care from a Global Perspective, we reported that people ...
Posted by Michael Wonder on 31 Jan 2023
Jazz Pharmaceuticals receives NICE recommendation for the reimbursement of Epidyolex (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex in England
31 January 2023 - Jazz Pharmaceuticals today announced that Epidyolex (cannabidiol 100 mg/mL oral solution), developed by GW Pharmaceuticals, has been ...
Posted by Michael Wonder on 31 Jan 2023
A watershed year for biosimilars — if regulators and policy makers step up
31 January 2023 - 31 January is set to mark the start of a watershed year for the biosimilars industry ...